Bedranol

Legal status and availability in the UK

In our online pharmacy, Bedranol is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Basic Bedranol information

• INN (international nonproprietary name): Propranolol (pro-PRAN-oh-lol).
• Brand names available in the United Kingdom: Bedranol, Inderal, Hemangeol, generic propranolol formulations.
• ATC code: C07AA05.
• Forms and strengths: tablets 10 mg, 40 mg, 80 mg, 160 mg; extended-release capsules 60 mg, 80 mg, 120 mg, 160 mg; Hemangeol oral solution 4.28 mg/mL for infantile haemangioma; IV ampoules 1 mg/mL for hospital use.
• Manufacturers: AstraZeneca, Teva, Sandoz and multiple generic manufacturers.
• Registration status in the United Kingdom: Rx-only; licensed formulations include tablets, modified-release formulations and Hemangeol oral solution.
• OTC / Rx classification: Prescription only (Rx).
• Standard adult dosages by condition: Hypertension 40 mg twice daily (start) then titrate to 120–240 mg/day; angina 80–320 mg/day divided; arrhythmias 10–30 mg TDS; migraine prophylaxis 80–240 mg/day; essential tremor 40 mg twice daily up to 320 mg/day; post‑MI 180–240 mg/day divided.
• Paediatric adjustment: Infantile haemangioma start 0.6 mg/kg twice daily, titrate to 1.7 mg/kg three times daily (Hemangeol); consult paediatric specialist for other paediatric uses.
• Storage and transport: Store 15–25°C, protect from moisture, heat and light; keep oral solutions tightly closed.

Clinical effectiveness in the UK

What can patients expect when propranolol is prescribed on the NHS?

Propranolol is an effective, widely used non‑selective beta‑blocker across hypertension, angina, arrhythmia control, migraine prophylaxis and essential tremor.

In primary care typical initiation for hypertension is 40 mg twice daily with stepwise up‑titration to maintenance doses commonly between 40–120 mg/day and occasionally to 120–240 mg/day where clinically required.

Migraine prophylaxis often uses doses between 80–160 mg/day with many patients reporting reduced attack frequency and severity at those levels.

For infantile haemangiomas NHS paediatric pathways now use Hemangeol oral solution (4.28 mg/mL) as the standard licensed option where indicated, typically for at least six months.

Common challenges include fatigue, sleep disturbance and cold extremities which can affect adherence.

Older adults more often report dizziness and orthostatic symptoms leading to dose reductions or discontinuation.

Local practice aligns with MHRA guidance and NICE/BNF recommendations for dosing and monitoring, and pharmacists routinely support adherence by counselling on side effects and dose titration.

Indications and expanded uses (MHRA‑approved and off‑label)

Patients commonly ask what propranolol treats and what it does not.

Licensed MHRA indications include hypertension, angina pectoris, certain arrhythmias, secondary prevention after myocardial infarction, migraine prophylaxis, essential tremor and infantile haemangioma (Hemangeol formulation).

Available formulations in product information are tablets 10–160 mg, modified‑release capsules and Hemangeol oral solution 4.28 mg/mL for infants.

Off‑label uses seen in NHS and private practice include performance anxiety for situational social anxiety, adjunctive treatment for akathisia, symptomatic control in thyrotoxicosis and selected PTSD symptom clusters.

These off‑label applications require documented informed consent and clear monitoring plans.

Preferred formulation and typical starting doses by indication are:

• Migraine prophylaxis: tablets, 80–240 mg/day divided.
• Essential tremor: tablets, 40 mg twice daily, up to 320 mg/day where tolerated.
• Infantile haemangioma: Hemangeol oral solution, start 0.6 mg/kg twice daily titrating to 1.7 mg/kg TDS per product info.

Licensed versus off‑label uses

• Licensed: cardiovascular indications, migraine prophylaxis, infantile haemangioma (Hemangeol).
• Off‑label: performance anxiety, akathisia adjunct, symptomatic thyrotoxicosis, selected PTSD uses — all need clinician oversight and consent.

Monitoring requirements vary by indication but routinely include pulse and blood pressure checks, review for bronchospasm symptoms and glucose awareness in at‑risk patients.

Composition and brand landscape (UK brands, generics, packaging)

Which brand should a prescriber or formulary manager choose?

INN: propranolol appears under several trade names in the UK market including Inderal and multiple generics, plus Hemangeol as the licensed infant oral solution.

Inderal is available in tablets 10, 40, 80 and 160 mg and modified‑release capsules are available as Inderal LA.

Generic propranolol tablets and propranolol ER formulations are widely supplied by companies such as Teva and Sandoz.

Supply considerations

• Supply continuity: check NHS Supply Chain and MHRA alerts for shortages.
• Formulation needs: availability of modified‑release options supports once‑daily regimens for adherence.

Hemangeol is supplied through paediatric specialist pathways.

Contraindications and special precautions (high‑risk groups)

Who should not take propranolol?

Absolute contraindications include asthma or active bronchospasm, severe bradycardia, high‑degree AV block unless a pacemaker is present, uncompensated heart failure and known hypersensitivity to propranolol or excipients.

Relative contraindications in UK practice include diabetes because hypoglycaemia symptoms may be masked, peripheral vascular disease, controlled heart failure, pregnancy and breastfeeding considerations, and severe hepatic impairment.

Practical precautions advise starting elderly patients on low doses with close orthostatic blood pressure monitoring and cautious titration in hepatic impairment because propranolol is hepatically metabolised and may accumulate.

Daily life restrictions to discuss with patients

• Avoid heavy alcohol intake which may potentiate sedation and hypotension.
• Be cautious driving if experiencing dizziness or visual disturbance.
• Athletes should check anti‑doping rules as beta‑blockers are restricted in certain sports.

Clinicians and pharmacists should use an explicit checklist distinguishing absolute versus relative contraindications on patient leaflets and report unexpected adverse events via the MHRA Yellow Card scheme.

Dosage guidelines (regimens and adjustments)

How is propranolol dosed across populations?

Standard adult initiation in UK practice for hypertension is 40 mg twice daily with titration according to response and tolerability; maintenance commonly falls between 40–120 mg/day but some indications require 120–240 mg/day.

Angina and secondary prevention after MI typically use 80–320 mg/day in divided doses depending on clinical need.

Arrhythmias often use 10–30 mg three times daily for chronic therapy with IV formulations used in acute hospital settings following local protocols.

Migraine prophylaxis is commonly 80–240 mg/day in divided doses and essential tremor usually starts at 40 mg twice daily with potential escalation to 320 mg/day under specialist advice.

Paediatric Hemangeol dosing: start at 0.6 mg/kg twice daily and titrate to 1.7 mg/kg three times daily per product information, with careful monitoring for hypoglycaemia.

Dosing adjustments

• Elderly and hepatic impairment: lower starting doses and slower titration with monitoring of pulse and blood pressure.
• Missed dose advice: take as soon as remembered unless close to next dose; do not double up.

For IV hospital use follow cardiology or acute care protocols and avoid abrupt cessation because rebound tachycardia and angina are risks.

Interactions overview (drugs and food)

Which medicines and foods interact with propranolol?

Key drug interactions include additive bradycardia or hypotension with calcium‑channel blockers such as verapamil and diltiazem and potentiation with other antihypertensives.

Metabolic interactions include potentiation of hypoglycaemia when combined with insulin or sulfonylureas and altered propranolol levels with CYP inhibitors or inducers.

Combined use of digoxin and propranolol increases the risk of AV block, and beta‑agonist bronchodilators may be less effective when a non‑selective beta‑blocker is used.

Food and drink considerations

Heavy alcohol intake can increase sedation and hypotension risk, and high caffeine intake may partially counteract beta‑blocker effects though this interaction is modest.

Severe bradycardia, bronchospasm and hypoglycaemia are clinically important events to monitor.

Interaction management

Comparable medicines and prescribing preferences (NHS alternatives)

Which alternatives should prescribers consider?

Common comparators in NHS practice include atenolol, metoprolol, bisoprolol and carvedilol with choices guided by beta‑selectivity, evidence for outcomes and comorbidities.

Cardioselective agents such as atenolol and metoprolol are preferred where asthma or bronchospasm is a concern, while bisoprolol and carvedilol have robust morbidity and mortality evidence in heart failure and post‑MI settings.

Propranolol's higher CNS penetration makes it particularly useful for migraine prophylaxis and performance anxiety but also leads to a greater likelihood of sleep disturbance and vivid dreams.

Points for prescribers

• Efficacy per indication — select drug with best evidence for the target condition.
• Adverse‑effect likelihood — choose cardioselective agents when respiratory risk exists.
• Drug interactions and polypharmacy — consider metabolic and additive effects.

Frequently asked questions

Q: Can I drive while taking propranolol?

A: If you experience dizziness, blurred vision or fatigue, avoid driving until symptoms settle and inform the DVLA if driving ability is affected.

Q: Can I stop propranolol suddenly?

A: No — do not stop abruptly; taper under clinician supervision to avoid rebound tachycardia or angina.

Q: Will propranolol affect my diabetes?

A: It can mask hypoglycaemia signs such as tachycardia; monitor glucose closely and liaise with your diabetes team when starting.

Q: Is propranolol safe in pregnancy or breastfeeding?

A: Use only if benefits outweigh risks; specialist obstetric and paediatric advice is recommended.

When to seek urgent care

• Severe breathlessness or wheeze.
• Syncope or collapse.
• Marked bradycardia or chest pain.

Guidelines for proper use (UK pharmacist counselling and NHS support)

What should pharmacists tell patients at point of supply?

Confirm the indication and formulation, for example tablet versus modified‑release capsule or Hemangeol for infants, and check contraindications such as asthma and high‑degree AV block.

Discuss common side effects like fatigue and vivid dreams and give clear missed‑dose advice, stressing not to double up on doses.

For Hemangeol, provide weight‑based dosing instructions, monitor feeding and watch for hypoglycaemia signs in infants, with immediate liaison to paediatric dermatology if concerns arise.

Document counselling in pharmacy records, signpost patients to NHS resources such as the BNF and MHRA and encourage Yellow Card reporting for adverse events.

Monitoring checklist for pharmacy records

• Pulse rate and blood pressure at baseline and after dose changes.
• Blood glucose monitoring in diabetic patients and infants.
• Respiratory symptom checks in those with past wheeze or COPD.

Local practice tips include using electronic prescriptions for repeat dispensing and offering pharmacist referrals to GPs for dose review or side‑effect management.

Delivery across the United Kingdom